top of page

Inflection Biosciences Announces Pre-clinical Data on IBL-202 to be Presented at ASH 2018 Meeting

Dublin, Ireland, November 22nd, 2018 – Inflection Biosciences Ltd, a private company developing innovative therapeutics for cancer, today announced that new data on IBL-202, a dual mechanism PIM/PI3 kinase inhibitor, will be highlighted in a poster at the 60th Annual Meeting of the American Society for Haematology (ASH), to be held December 1-4, 2018 in San Diego, California.

The pre-clinical data was generated through a collaboration with Dr. Giles Best of the Northern Blood Research Centre, Kolling Institute of Medical Research, University of Sydney, Australia, and a member of the CLL Australian Research Consortium (CLLARC), Sydney, Australia.

The details for the poster presentations are as follows:

Poster Title: The Dual PI3/PIM-Kinase Inhibitor, IBL-202, Is Highly Synergistic with Venetoclax Against CLL Cells, and TP53-Knock-out Cells, and Under Conditions That Mimic the Tumor Microenvironment

Poster Session Category: 642 CLL: Therapy, excluding Transplantation

Time & Date: 6.15 pm – 8.15 pm; Saturday, December 1, 2018

Presenter: Yandong Shen

Abstract Number: 1870

Poster Board Number: 1

Location: Hall GH (San Diego Convention Center)

The full abstract can be viewed here.

About PIM/PI3 kinase inhibitors

The PI3K/AKT pathway is commonly activated in human cancer. Multiple small-molecule inhibitors have been developed to target PI3K/mTOR or AKT kinases, but the efficacy of these drugs is compromised by the stimulation of compensatory signalling pathways. One example of such compensatory pathways is that driven by PIM kinases, which produce parallel oncogenic signals to AKT and mTOR and share several downstream molecular targets. Therefore, combined inhibition of such activities in a single molecule might have the potential to achieve better clinical efficacy and prevent/suppress resistance in comparison with classical PI3K/AKT/mTOR inhibitors.

About Inflection Biosciences

Inflection Biosciences Ltd, based in Dublin and London, is developing small molecule therapeutics for the treatment of cancer. The company's pipeline of highly innovative cancer treatments was licensed from the Spanish National Cancer Research Centre (CNIO). The pipeline comprises the IBL-300 series (PIM/PI3K/mTOR inhibitors) and IBL-202 (PIM/PI3K inhibitor) selected from a series of unique dual mechanism kinase inhibitors and the IBL-100 series (selective pan-PIM kinase inhibitors), currently in pre-clinical stages of development. Data generated to date suggests potential application in a range of treatment resistant solid tumours and haematological malignancies. Inflection Biosciences was named ‘Start-up Company of the Year’ at the 2014 Irish Pharma Awards. For more information please visit


bottom of page